Novel inhaled andrographolide for treatment of lung cancer: in vitro assessment

Andrographolide is a plant-based compound that showed promising activity against lung cancer. However, the compound's poor water solubility and low bioavailability limit its oral administration. Inhaled drug delivery of andrographolide is highly favourable as it delivers active ingredients dire...

Full description

Saved in:
Bibliographic Details
Main Authors: Masarudin, Mas Jaffri, Jothi. N, Arul, Mohtar, Noratiqah, Parumasivam, Thaigarajan
Format: Article
Language:English
Published: Elsevier Ltd 2024
Online Access:http://psasir.upm.edu.my/id/eprint/111592/1/PIIS2405844024067926.pdf
http://psasir.upm.edu.my/id/eprint/111592/
https://www.sciencedirect.com/science/article/pii/S2405844024067926
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universiti Putra Malaysia
Language: English
id my.upm.eprints.111592
record_format eprints
spelling my.upm.eprints.1115922024-08-04T09:35:26Z http://psasir.upm.edu.my/id/eprint/111592/ Novel inhaled andrographolide for treatment of lung cancer: in vitro assessment Masarudin, Mas Jaffri Jothi. N, Arul Mohtar, Noratiqah Parumasivam, Thaigarajan Andrographolide is a plant-based compound that showed promising activity against lung cancer. However, the compound's poor water solubility and low bioavailability limit its oral administration. Inhaled drug delivery of andrographolide is highly favourable as it delivers active ingredients directly into the affected lungs. In the current study, we compared in vitro aerosol performance, anti-cancer activity and storages stability of two (2) inhalable andrographolide formulations. Formulation 1 was prepared using precipitation and spray drying techniques, while Formulation 2 was prepared via direct spray drying technique. Drug morphology and physicochemical properties were confirmed using scanning electron microscopy (SEM) and X-ray diffraction (XRD) analysis. In vitro aerosol dispersion profile was evaluated using the next-generation impactor (NGI). Formulation 1 consisted of elongated crystals while Formulation 2 was made up of amorphous spherical particles. Both formulations had an inhalable fraction (<5 μm) of more than 40 %, making them suitable for pulmonary drug delivery. The formulations also showed an IC25 of less than 100 μg/mL against the human lung carcinoma cells (A549). Formulation 1 and 2 was stable in a vacuum condition at 30 °C for up to 6 and 3 months, respectively. Novel inhalable andrographolide dry powders were successfully produced with a good aerosol profile, potent anti-cancer activity and adequate storage stability, which deserve further in vivo investigations. Elsevier Ltd 2024-05-04 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/111592/1/PIIS2405844024067926.pdf Masarudin, Mas Jaffri and Jothi. N, Arul and Mohtar, Noratiqah and Parumasivam, Thaigarajan (2024) Novel inhaled andrographolide for treatment of lung cancer: in vitro assessment. Heliyon, 10 (9). art. no. e30761. pp. 1-12. ISSN 2405-8440 https://www.sciencedirect.com/science/article/pii/S2405844024067926 10.1016/j.heliyon.2024.e30761
institution Universiti Putra Malaysia
building UPM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Putra Malaysia
content_source UPM Institutional Repository
url_provider http://psasir.upm.edu.my/
language English
description Andrographolide is a plant-based compound that showed promising activity against lung cancer. However, the compound's poor water solubility and low bioavailability limit its oral administration. Inhaled drug delivery of andrographolide is highly favourable as it delivers active ingredients directly into the affected lungs. In the current study, we compared in vitro aerosol performance, anti-cancer activity and storages stability of two (2) inhalable andrographolide formulations. Formulation 1 was prepared using precipitation and spray drying techniques, while Formulation 2 was prepared via direct spray drying technique. Drug morphology and physicochemical properties were confirmed using scanning electron microscopy (SEM) and X-ray diffraction (XRD) analysis. In vitro aerosol dispersion profile was evaluated using the next-generation impactor (NGI). Formulation 1 consisted of elongated crystals while Formulation 2 was made up of amorphous spherical particles. Both formulations had an inhalable fraction (<5 μm) of more than 40 %, making them suitable for pulmonary drug delivery. The formulations also showed an IC25 of less than 100 μg/mL against the human lung carcinoma cells (A549). Formulation 1 and 2 was stable in a vacuum condition at 30 °C for up to 6 and 3 months, respectively. Novel inhalable andrographolide dry powders were successfully produced with a good aerosol profile, potent anti-cancer activity and adequate storage stability, which deserve further in vivo investigations.
format Article
author Masarudin, Mas Jaffri
Jothi. N, Arul
Mohtar, Noratiqah
Parumasivam, Thaigarajan
spellingShingle Masarudin, Mas Jaffri
Jothi. N, Arul
Mohtar, Noratiqah
Parumasivam, Thaigarajan
Novel inhaled andrographolide for treatment of lung cancer: in vitro assessment
author_facet Masarudin, Mas Jaffri
Jothi. N, Arul
Mohtar, Noratiqah
Parumasivam, Thaigarajan
author_sort Masarudin, Mas Jaffri
title Novel inhaled andrographolide for treatment of lung cancer: in vitro assessment
title_short Novel inhaled andrographolide for treatment of lung cancer: in vitro assessment
title_full Novel inhaled andrographolide for treatment of lung cancer: in vitro assessment
title_fullStr Novel inhaled andrographolide for treatment of lung cancer: in vitro assessment
title_full_unstemmed Novel inhaled andrographolide for treatment of lung cancer: in vitro assessment
title_sort novel inhaled andrographolide for treatment of lung cancer: in vitro assessment
publisher Elsevier Ltd
publishDate 2024
url http://psasir.upm.edu.my/id/eprint/111592/1/PIIS2405844024067926.pdf
http://psasir.upm.edu.my/id/eprint/111592/
https://www.sciencedirect.com/science/article/pii/S2405844024067926
_version_ 1806512716600311808